[SCHEDULE 13G] FibroBiologics, Inc. Passive Investment Disclosure (>5%)

FibroBiologics, Inc. Schedule 13G shows Lind Global Fund III LP and related reporting persons beneficially own 230,234 shares, representing 4.99% of common stock.

Rhea-AI Filing Summary

FibroBiologics, Inc. Schedule 13G shows Lind Global Fund III LP and related reporting persons beneficially own 230,234 shares, representing 4.99% of common stock. The filing explains the position reflects 157,956 shares plus 540,536 warrants whose conversion is contractually limited to avoid ownership above 4.99%.

Insights

Corporate Governance Analyst

Passive 13G filing shows capped warrant conversion keeps Lind below 5%.

The filing records an aggregate beneficial ownership of 230,234 shares and explains that 540,536 warrants include a conversion cap preventing ownership above 4.99%. This indicates passive investment status under the reporting schedule.

Watch for any future amendments if conversion terms change or if the holder exceeds the 4.99% threshold, which would alter reporting status.

Key Figures

Beneficial ownership: 230,234 shares Percent of class: 4.99% Common shares held: 157,956 shares +3 more

6 metrics

Beneficial ownership 230,234 shares aggregate beneficial ownership reported

Percent of class 4.99% percent of common stock reported

Common shares held 157,956 shares reported owned common stock component

Warrants outstanding (reporting) 540,536 warrants warrants to purchase common stock with conversion limits

CUSIP 31573L204 identifier for common stock class

Filing date / signature date 04/09/2026 signature date on Schedule 13G

Key Terms

beneficial ownership, conversion limitations, sole dispositive power

3 terms

beneficial ownership regulatory

"See Row 9 of cover page for each Reporting Person"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

conversion limitations financial

"the Warrants include a provision limiting the holder's ability to convert the Warrants"

sole dispositive power regulatory

"Sole Dispositive Power 230,234.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Lind Global report in FibroBiologics (FBLG)?

Lind Global reports beneficial ownership of 230,234 shares, equal to 4.99% of common stock. The position consists of 157,956 shares plus 540,536 warrants whose conversion is limited to prevent ownership above the 4.99% threshold.

Why is Lind Global's ownership capped at 4.99% in the 13G?

The warrants include a contractual conversion limitation that prevents conversion if it would cause beneficial ownership to exceed 4.99%. That provision limits the effective shares counted for beneficial ownership to 230,234 in aggregate as stated in the filing.

Does the 13G indicate Lind Global has voting or dispositive power?

Yes; the filing states Lind Global Fund III LP and related reporting persons have sole voting and sole dispositive power over 230,234 shares. Lind Global Partners III LLC is the general partner and Jeff Easton may be deemed to have such authority.

Will this 13G trigger different reporting requirements if Lind exceeds 5%?

Exceeding 5% would change reporting classification and likely require amended filings such as a Schedule 13D. The current filing notes the conversion limit prevents exceeding 4.99%, keeping the position within Schedule 13G passive reporting rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:30 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FibroBiologics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

31573L204

(CUSIP Number)

04/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 31573L204

1

Names of Reporting Persons

Lind Global Fund III LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 230,234.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 230,234.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

230,234.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 157,956 shares of common stock and (ii) 540,536 warrants to purchase shares of common stock (the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 230,234 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP Number(s): 31573L204

1

Names of Reporting Persons

Lind Global Partners III LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 230,234.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 230,234.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

230,234.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 157,956 shares of common stock and (ii) 540,536 warrants to purchase shares of common stock (the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 230,234 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP Number(s): 31573L204

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 230,234.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 230,234.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

230,234.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 157,956 shares of common stock and (ii) 540,536 warrants to purchase shares of common stock (the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 230,234 shares in the aggregate. (2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: FibroBiologics, Inc.
(b)	Address of issuer's principal executive offices: 55 E. Medical Center Blvd, Suite 300, Houston, Texas, 77598
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund III LP, a Delaware limited partnership; o Lind Global Partners III LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP. Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.00001 par value
(e)	CUSIP Number(s): 31573L204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature:	By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	04/09/2026

Lind Global Partners III LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	04/09/2026

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	04/09/2026

Exhibit Information

99.1 Joint Filing Agreement by and among the Reporting Persons.